Synapse - Advanced Practice Providers

Results (27)

Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma

Research Letter

Lin, R. J.; Kim, S. J.; Brown, S.; Elko, T. A.; Ruiz, J. D.; Hanley, D. M.; Palomba, M. L.; Perales, M. A.; Shah, G. L.; Dahi, P. B.; more...
Blood Advances (2023)

Fulltext@MSK | Save

Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
Blood (2022)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence

Meeting Abstract

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
Blood (2021)

Fulltext@MSK | Save

Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)

Meeting Abstract

Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
Blood (2021)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial

Journal Article

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
The Lancet Haematology (2021)

Fulltext@MSK | Save

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Journal Article

Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J. R.; Shouval, R.; Alarcon Tomas, A.; Silverberg, M. L.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Devlin, S. M.; more...
Blood Advances (2021)

Fulltext@MSK | Save

Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma

Meeting Abstract

Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

The International Prognostic Index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy

Journal Article

Garcia-Recio, M.; Wudhikarn, K.; Pennisi, M.; Alonso-Trillo, R.; Flynn, J.; Shouval, R.; Afuye, A. O.; Silverberg, M. L.; Batlevi, C. W.; Dahi, P.; more...
Transplantation and Cellular Therapy (2021)

Fulltext@MSK | Save

Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma

Research Letter

Lin, R. J.; Lobaugh, S. M.; Pennisi, M.; Chan, H. T.; Batlevi, Y.; Ruiz, J. D.; Elko, T. A.; Maloy, M. A.; Batlevi, C. L.; Dahi, P. B.; more...
Haematologica (2021)

Fulltext@MSK | Save

Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
Blood (2020)

Fulltext@MSK | Save